Effect of Laparoscopic Splenectomy on Lipid Profiles in Cirrhotic Patients With Hypersplenism (2-Year Follow-Up)

Starting soon

Conditions studied: Cirrhosis, Splenectomy; Status, Hypersplenism, Lipid Profiles

In brief

Patients with liver cirrhosis frequently exhibit dyslipidemia due to impaired hepatic lipid synthesis, altered bile acid metabolism, and portal hypertension. Laparoscopic splenectomy is commonly used to treat splenomegaly and hypersplenism in these patients, but its impact on lipid profiles over 2 years remains poorly characterized. This study will follow patients undergoing laparoscopic splenectomy to measure changes in serum lipid parameters before and after surgery, identify risk factors for lipid profile deterioration or improvement, and determine whether laparoscopic splenectomy can ameliorate dyslipidemia in the long term, thereby informing metabolic management strategies in cirrhotic patients.

Key facts

Study ID

NCT07588373

Run by

Northern Jiangsu People's Hospital

People needed

30

Starts

2026-05-01

Expected to finish

2029-02-28

Last updated by the study team

2026-05-14

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18-80 years, male or female
• Confirmed diagnosis of liver cirrhosis (clinical, laboratory, imaging)
• Splenomegaly and hypersplenism
• Child-Pugh Class A or B liver function
• Signed written informed consent
• Ability to complete 24-month follow-up

You may not qualify if…

• Child-Pugh Class C liver cirrhosis
• No history of portal hypertension bleeding (esophageal and gastric variceal bleeding )
• Previous abdominal surgery precluding safe laparoscopic splenectomy.
• Severe cardiac, pulmonary, cerebrovascular dysfunction; malignant tumors; primary hematological disorders
• Metabolic/endocrine diseases: Familial hyperlipidemia; uncontrolled severe diabetes mellitus, thyroid dysfunction, nephrotic syndrome; use of lipid-lowering drugs, hormones, or other drugs affecting blood lipids within 1 month before surgery.
• Infections/inflammatory diseases: Active hepatitis, severe infections, or autoimmune diseases.
• Cirrhotic complications (hepatic encephalopathy, refractory ascites) within 1 month before surgery
• Pregnancy or lactation
• Poor compliance, inability to complete follow-up

Where it is running

• Clinical Medical College of Yangzhou University — Yangzhou, Jiangsu, China

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.